ABT 最新 8-K 归类为其他事项。缓存主文档中没有确定性提取器可引用的实质性段落。
公司概览 · 有来源可查
Abbott Laboratories
ABT公司证据档案
Abbott Laboratories 的历史市场背景与近期 SEC 披露。本视图使用当前本地证据快照。
- 最新复权收盘价
- $103.70观测于 2026-10-23
- 相对 SPY 的回报差
- -87.92021-10-25 至 2026-10-23
- 快照内的披露数量
- 5价格区间 1980-03-17 至 2026-10-23
价格字段：vendor-adjusted closeSEC EDGAR company recordCIK 0000001800
摘要
先读这里，再到下方逐项核对。
三句话，并标明各自属于哪一类陈述。其中每个数字都能在本页下方找到来源。
在所选历史期间, ABT 累计回报为 -9.5%, 最大回撤为 -39.6%。这些是历史观测, 不是预测。
本地快照覆盖 SEC 披露、可用时的最新重述年度 Company Facts，以及复权日线价格。它不构成估值、未来回报或投资建议。
生成方式：deterministic_fallback · 这些是历史观测，不是预测。
申报结果
最近财报说了什么
来自 10-Q 的季度数据，报告期截至 2026-06-30，披露于 2026-07-28。全部取自同一份报告，因此期间与会计口径始终与数值一致。
已找到报告，但无法提取数值
报告已定位，但没有数值同时满足本页所需的报告期与会计口径，因此不展示近似值。
报告列示的合并财务数据。不同公司的会计处理与业务构成仍有差异，已申报的结果也不是预测。
历史与风险
过去走成什么样，过程有多颠簸
所选区间内的复权日线价格，与 SPY 比较。SPY 是跟踪标普 500 指数的交易所交易基金。
ABTSPY复权日收盘价
期末价值$9,050以 $10,000 起始投入，2021-10-25 至 2026-10-23
相对 SPY 的回报差（百分点）-87.9ABT -9.5% · SPY +78.4%
累计回报-9.5%2021-10-25 至 2026-10-23
年化回报-2%所示区间内的复合增长率
年化波动率23.1%日收益率年化
最大回撤-39.6%低点 2026-05-11
相对 SPY 的 Beta0.49对基准波动的敏感度
与 SPY 的相关性0.371,255 个对齐交易日
实际体验如何该区间内从高点到低点的最大跌幅为 -39.6%，单日最差为 -10%。两者都已经发生，也都不构成对未来的上限。
只有本节跟随基准选择器。摘要、披露反应与 AI 证据仍使用 SPY；本图当前显示的是 SPY。
历史回报与风险是对一段已经结束的时期的观测，不是预测，本页内容也不构成投资建议。
原始披露
申报了什么
SEC 检查于 2026-10-24
披露文件本身。公司披露的内容与本项目对其所做的测量分开呈现。
8-K其他事项2026-10-21 17:19披露后 +1.3%
- 其他事项
- 财务报表与附件
无法从缓存的主文档中确定性地提取段落，因此不作引用。
与上一份可比披露的对照
与 2026-04-18 受理的那份相比：0 处变更，1 处新增，1 处删除。
新增
原文为英文（申报文本）
false 0000001800 Common Shares, Without Par Value ABT 0000001800 2026-10-21 2026-10-21 0000001800 us-gaap:CommonStockMember exch:XCHI 2026-10-21 2026-10-21 0000001800 us-gaap:CommonStockMember exch:XNYS 2026-10-21 2026-10-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
删除
8-K经营业绩(财报)2026-10-21 15:36披露后 +1.3%
- 经营业绩(财报)
- 财务报表与附件
文件原文摘录
原文为英文（申报文本）
Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results.
原文段落
原文为英文（申报文本）
These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, legal settlements, stock-based compensation recognized as expense from equity awards accelerated in connection with an acquisition, restructuring actions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation.
原文段落
原文为英文（申报文本）
These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance.
原文段落
与上一份可比披露的对照
与 2026-07-16 受理的那份相比：1 处变更，1 处新增，1 处删除。
内容变更 · 文本相似度 67%
原文为英文（申报文本）
abt-20261021 0000001800 FALSE New York Stock Exchange CHX 0000001800 2026-10-21 2026-10-21 0000001800 exch:XNYS 2026-10-21 2026-10-21 0000001800 exch:XCHI 2026-10-21 2026-10-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
新增
原文为英文（申报文本）
These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, legal settlements, stock-based compensation recognized as expense from equity awards accelerated in connection with an acquisition, restructuring actions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation.
8-KRegulation FD 披露2026-08-21 00:33披露后 +2.3%
- Regulation FD 披露
- 其他事项
- 财务报表与附件
文件原文摘录
原文为英文（申报文本）
On August 20, 2026, rather than continuing to appeal or paying approximately $600 million (representing the Gill judgment plus accrued interest to date), Abbott entered into agreements to resolve the Gill lawsuit as well as NEC claims asserted on behalf of approximately 2,000 additional infants for an aggregate amount of approximately $670 million.
原文段落
原文为英文（申报文本）
In a July 2024 Missouri state court trial, a jury awarded a plaintiff (“ Gill ”) $495 million in damages, which Abbott appealed to the Missouri Court of Appeals in December 2024.
原文段落
原文为英文（申报文本）
These agreements are a compromise of disputed claims and not in any way an admission of liability.
原文段落
文件中的数字
- $600 million
- $670 million
- $495 million
与上一份可比披露的对照
与 2022-02-18 受理的那份相比：1 处变更，10 处新增，9 处删除。
内容变更 · 文本相似度 81%
原文为英文（申报文本）
false 0000001800 Common Shares, Without Par Value ABT 0000001800 2026-08-20 2026-08-20 0000001800 us-gaap:CommonStockMember exch:XCHI 2026-08-20 2026-08-20 0000001800 us-gaap:CommonStockMember exch:XNYS 2026-08-20 2026-08-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
新增
原文为英文（申报文本）
On August 20, 2026, rather than continuing to appeal or paying approximately $600 million (representing the Gill judgment plus accrued interest to date), Abbott entered into agreements to resolve the Gill lawsuit as well as NEC claims asserted on behalf of approximately 2,000 additional infants for an aggregate amount of approximately $670 million.
8-K经营业绩(财报)2026-07-16 15:36披露后 -0.5%
- 经营业绩(财报)
- 财务报表与附件
文件原文摘录
原文为英文（申报文本）
Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results.
原文段落
原文为英文（申报文本）
These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, legal reserves, stock-based compensation recognized as expense from equity awards accelerated in connection with an acquisition, restructuring actions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation.
原文段落
原文为英文（申报文本）
These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance.
原文段落
与上一份可比披露的对照
与 2026-04-16 受理的那份相比：1 处变更，1 处新增，1 处删除。
内容变更 · 文本相似度 71%
原文为英文（申报文本）
abt-20260716 0000001800 FALSE New York Stock Exchange CHX 0000001800 2026-07-16 2026-07-16 0000001800 exch:XCHI 2026-07-16 2026-07-16 0000001800 exch:XNYS 2026-07-16 2026-07-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
新增
原文为英文（申报文本）
These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, legal reserves, stock-based compensation recognized as expense from equity awards accelerated in connection with an acquisition, restructuring actions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation.
8-K董事或主要高管变更2026-04-28 00:06披露后 +0.0%
- 董事或主要高管变更
- 财年或章程修订
- 股东投票结果
- 财务报表与附件
文件原文摘录
原文为英文（申报文本）
The 2026 Program, which is administered by the Compensation Committee of Abbott’s Board of Directors, permits Abbott to grant nonqualified stock options, restricted stock awards, restricted stock units, performance awards, and other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards) to non-employee directors and employees of Abbott and its subsidiaries.
原文段落
与上一份可比披露的对照
与 2025-12-13 受理的那份相比：0 处变更，12 处新增，2 处删除。
新增
原文为英文（申报文本）
The 2026 Program, which is administered by the Compensation Committee of Abbott’s Board of Directors, permits Abbott to grant nonqualified stock options, restricted stock awards, restricted stock units, performance awards, and other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards) to non-employee directors and employees of Abbott and its subsidiaries.
新增
原文为英文（申报文本）
On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual Meeting of Shareholders.
更早的披露
每条附带其后首个符合条件交易日相对基准的涨跌幅。这是对幅度的测量，不是因果关系。
- 2026-03-23其他事项2026-03-24 -0.3%原始文件
- 2026-04-16经营业绩(财报)2026-04-17 +0.7%原始文件
- 2026-04-18其他事项2026-04-20 -0.5%原始文件
- 2026-04-28董事或主要高管变更2026-04-28 +0.0%原始文件
- 2026-07-16经营业绩(财报)2026-07-17 -0.5%原始文件
- 2026-08-21Regulation FD 披露2026-08-21 +2.3%原始文件
- 2026-10-21经营业绩(财报)2026-10-22 +1.3%原始文件
- 2026-10-21其他事项2026-10-22 +1.3%原始文件
事件与接下来关注
最近发生了什么，接下来看什么
事件条目是已发布的新闻标题与申报索引记录，并附来源链接。它们不是分析，事件源也不是交易信号。
有证据支撑的研究
就这些证据提问
回答只依据这家公司的证据包。引用与数字会先对照该证据包校验，未通过校验的答案不会展示。
不生成投资建议、目标价或方向性预测；提出此类问题会被拒答。